AIMS: The goal of this study was to assess the efficacy and tolerability of tianeptine in combination with selective serotonin re-uptake inhibitor (SSRI) in partial responders or non-responders to SSRI monotherapy. METHODS: In this prospective, open-label, 6-week study, 150 patients with major depressive disorder who had previously not responded or partially responded to SSRI monotherapy were recruited. Tianeptine was given in combination with an SSRI for 6 weeks. RESULTS: Significant improvements were observed in the mean scores of the Hamilton Depression Rating Scale (HDRS), Montgomery-Åsberg Depression Rating Scale (MADRS), and Clinical Global Impression-Severity (CGI-S). The change in the mean HDRS, MADRS, and CGI-S scores was significant from week 1. The response rates were 64.7% (HDRS) and 68.7% (MADRS), and the remission rates were 34.0% (HDRS) and 42.0% (MADRS) at week 6. Thirty-six patients (24.0%) reported adverse events that were determined by the investigator to be related to one of the study drugs. The tianeptine and SSRI combination was generally well-tolerated. CONCLUSIONS: A combination strategy with tianeptine may be an effective and well-tolerated tool for patients who have failed to adequately respond to SSRI monotherapy.
AIMS: The goal of this study was to assess the efficacy and tolerability of tianeptine in combination with selective serotonin re-uptake inhibitor (SSRI) in partial responders or non-responders to SSRI monotherapy. METHODS: In this prospective, open-label, 6-week study, 150 patients with major depressive disorder who had previously not responded or partially responded to SSRI monotherapy were recruited. Tianeptine was given in combination with an SSRI for 6 weeks. RESULTS: Significant improvements were observed in the mean scores of the Hamilton Depression Rating Scale (HDRS), Montgomery-Åsberg Depression Rating Scale (MADRS), and Clinical Global Impression-Severity (CGI-S). The change in the mean HDRS, MADRS, and CGI-S scores was significant from week 1. The response rates were 64.7% (HDRS) and 68.7% (MADRS), and the remission rates were 34.0% (HDRS) and 42.0% (MADRS) at week 6. Thirty-six patients (24.0%) reported adverse events that were determined by the investigator to be related to one of the study drugs. The tianeptine and SSRI combination was generally well-tolerated. CONCLUSIONS: A combination strategy with tianeptine may be an effective and well-tolerated tool for patients who have failed to adequately respond to SSRI monotherapy.
Authors: Benjamin Adam Samuels; Katherine M Nautiyal; Andrew C Kruegel; Marjorie R Levinstein; Valerie M Magalong; Madalee M Gassaway; Steven G Grinnell; Jaena Han; Michael A Ansonoff; John E Pintar; Jonathan A Javitch; Dalibor Sames; René Hen Journal: Neuropsychopharmacology Date: 2017-03-17 Impact factor: 7.853
Authors: Jaena Han; Valentine Andreu; Cory Langreck; Elizabeth A Pekarskaya; Steven G Grinnell; Florence Allain; Valerie Magalong; John Pintar; Brigitte L Kieffer; Alexander Z Harris; Jonathan A Javitch; René Hen; Katherine M Nautiyal Journal: Neuropsychopharmacology Date: 2021-09-30 Impact factor: 8.294
Authors: Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein Journal: Am J Drug Alcohol Abuse Date: 2021-04-28 Impact factor: 3.912
Authors: Małgorzata Szafarz; Agnieszka Wencel; Krzysztof Pociecha; Filip A Fedak; Piotr Wlaź; Elżbieta Wyska Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-12-12 Impact factor: 3.000